Discussion  by unknown
dependent outcomes, there are numerous variables that were
related to outcome both in a univariate fashion, multivariate
fashion, or both. All of these can be important when trying to
predict the early and late outcome of an operation. Table 7
provides a summary of the variables that were statistically
significantly associated with 1 or more of the dependent out-
come variables in a multivariate model.
In conclusion, it appears that male sex, RVOT obstruction
(including pulmonary stenosis and hypoplastic or stenotic
pulmonary arteries), MV regurgitation requiring surgical
intervention, cyanosis, and of the RV and/or LV systolic
dysfunction are among the more important preoperative
variables that are predictive of higher mortality. These vari-
ables should be helpful in stratifying patients’ potential oper-
ative risk.
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DDiscussion
Dr Vaughan A. Starnes (Los Angeles, Calif). I would like to con-
gratulate Dr Dearani on an excellent and clear presentation. Dr Dear-
ani and his colleagues have presented a comprehensive review of the
Mayo Clinic’s experience with surgical treatment of 539 patients
with Ebstein anomaly over a 34-year period of time. I believe this
represents the largest and most comprehensive review thus far.
The Mayo operation consisted of TVrpl in 61%, TVrpr in 34%, con-
comitant ASD closure in 84% and plication of the right ventricle in
35%, and ablation of the pathway in 13%. The early mortality was
excellent at a low value of 6%, and the overall survival of the entire
cohort treated at 10 and 20 years was 85% and 71%, respectively.
An extensive analysis of variables predicting early and late mortalityy 2008
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Dwere analyzed. As we have seen in the presentation, a multivariant
analysis was performed, and predictors of overall mortality were mi-
tral regurgitation, moderate-to-severe RV dysfunction, RVOT or
pulmonary artery reconstruction, and TVrpl.
This leads me to my first question, Joe, which is one of 3.
In your paper and presentation TVrpr is advocated and seems to
be related to better survival, and yet it seems you have replaced more
valves than you repaired, and this tendency seems to be increasing in
the more recent experience. Based on this large experience, what are
the determinants currently used to see whether the valve is repair-
able, and what degree of insufficiency would you accept?
Dr Dearani. Thank you for your remarks, Dr Starnes. We prefer
TVrpr when the valve is repairable. In recent years, there has been
a tendency for more replacement, which we believe is the result of
2 major reasons. First, in the adult population the durability of a tri-
cuspid bioprosthesis is excellent, and the freedom from reoperation
is actually much better with a bioprosthesis than with a fair repair.
The second reason is that recently there has been a greater percent-
age of patients who have already undergone a previous operation
elsewhere, and in our experience the chances to rerepair a valve in
that setting are rarely successful.
Dr Starnes. My second question—and I think I know your bias
but to clarify it—if the valve is to be replaced, which valve are we
going to use, a mechanical or a tissue valve?
Dr Dearani. Of approximately 350 TVrpls, about 300 were bio-
prosthetic, and 45 were mechanical. We prefer bioprostheses for 2
reasons: first, the durability is excellent, and second, our ability to
successfully treat atrial arrhythmias with the concomitant maze pro-
cedure has improved in recent years. Consequently, we are able to
optimize the ability to spare the patient from long-term warfarin an-
ticoagulation.
The patients we would consider for mechanical TVrpl would re-
ally be those who require anticoagulation for another reason, specif-
ically a left-sided mechanical prosthesis, which occurs very
infrequently. There are some important observations that we have
made with regard to mechanical TVrpl in Ebstein anomaly that
are worth mentioning. First, it is easy to insert a very large prosthesis
because the true tricuspid annulus is usually severely dilated. Cau-
tion should be exercised that the prosthesis is not oversized when
a mechanical valve is being used. In the presence of RV dysfunction,
which is always present in Ebstein anomaly, the discs might not
open and close normally. Thus the risk of thrombosis-related prob-
lems with a mechanical prosthesis is greater in this setting, and
therefore there is a need for even stronger anticoagulation. For all
of these reasons, we prefer a porcine bioprosthesis when valve re-
placement is required.
Dr Starnes. The last question, Joe, and maybe the most difficult
to answer is this: Given the variability of a clinical presentation of
Ebstein anomaly and your extensive experience, when should a pa-
tient undergo an operation?
Dr Dearani. The timing of the operation can be challenging for
some patients. In general, clinical deterioration and progressive
symptomatology with Ebstein anomaly occurs over a long period
of time, generally years. Consequently, it is uncommon to advise
an operation at the initial outpatient visit. When symptoms are ab-
sent, the decision to operate is usually based on serial changes
that occur on echocardiograms. We have learned from this study
that the presence of significant RV dysfunction is a powerful predic-The Journal of Thorator of outcome. With this in mind, an operation should be advised
before significant RV dysfunction, and I will say that that is not al-
ways easy to ascertain. Determination of RV function is challeng-
ing. We currently use both echocardiographic analysis and
magnetic resonance imaging to quantitate the function of the right
ventricle, and on many occasions we have found marked discrep-
ancies in the results between these 2 diagnostic modalities. We con-
tinue to learn from both echocardiography and magnetic resonance
imaging, but at the current time, there are limitations for both.
Other indications for surgical intervention include abnormal ex-
ercise tolerance, cyanosis, the presence or progression of arrhyth-
mias, and progressive increase in RV size. If echocardiography
suggests high probability of TVrpr, then we would advise an earlier
operation.
Dr Starnes. Again, I would like to congratulate the author on an
excellent presentation and the manuscript that was given to me in
advance, and I would like to thank the Association for the floor.
Dr Afksendiyos Kalangos (Geneva, Switzerland). How do you
evaluate RV function, by means of echocardiography or magnetic
resonance imaging, and what are the criteria for RV dysfunction
of more than moderate degree?
Dr Dearani. As I indicated earlier, echocardiography is very im-
perfect. In my experience echocardiography can tell you whether the
RV function is good or whether it is bad; everything in between is
very difficult to quantitate. Magnetic resonance imaging evaluation
appears to be more objective in terms of being able to provide an
ejection fraction. However, in a given patient there have been cir-
cumstances when the echocardiography suggested good RV func-
tion and the magnetic resonance imaging suggested poor RV
function and vice versa.
Therefore there is a lot to be learned in terms of quantitating RV
function in Ebstein anomaly. I do not have the answer. It is very
imperfect.
Dr Antonio Corno (Liverpool, United Kingdom). I enjoyed the
presentation. You presented a very small number of patients with
one and a half type of ventricular repair, and you say these have
been done in the last few years. Actually, you are limiting the indi-
cation to one and a half ventricular repair to the patient with severe
RV dysfunction. Do you consider that if you largely extend the in-
dication to one and a half ventricular repair, as done in other series,
you can dramatically reduce the number of TVrpls? If you use the
one and a half ventricular type of repair, you reduce one third of
the systemic venous return through the TV, and this is allowing
you to do a much better TVrpr in terms of reduced degree of residual
stenosis or regurgitation, and this would allow you to reduce the
need for TVrpl.
Dr Dearani. I agree. The point that is being made is whether the
addition of a bidirectional Glenn shunt improves the percentage of
successful repairs, and I think the answer is, in general, yes. With
that in mind, the bidirectional Glenn shunt is not a perfect solution
either. One issue with Ebstein anomaly that we are going to inves-
tigate in the future is exercise tolerance in patients who have had a bi-
ventricular repair with TVrpl versus those patients who have had
a bidirectional Glenn shunt (ie, a one and a half ventricle repair).
The one and a half ventricle repair, in my experience, helps re-
duce the early mortality in patients with profound RV dysfunction,
but the late results with the bidirectional Glenn shunt are unclear. In
addition, in this patient subgroup there is a high probability of latecic and Cardiovascular Surgery c Volume 135, Number 5 1135
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Darrhythmias, and the bidirectional Glenn shunt does affect the ability
to access the heart in the standard fashion for electrophysiologic
evaluation. Reducing the volume and size of the right ventricle
with a bidirectional Glenn shunt might enable a greater number of
successful tricuspid repairs by decreasing tension on suture lines
and allowing for a smaller annulus size without creating tricuspid
stenosis. At the current time, we apply the bidirectional Glenn shunt
selectively.
Dr Pedro Becker (Santiago, Chile). Do you have information
on whether the RV dysfunction gets better after surgical interven-
tion? Did you evaluate that and whether it is related to prognosis?
Also, what has been your incidence of heartbeat block in TVrpl?
DrDearani. In our experience the incidence of heart block is 2%
or less with TVrpl. We place the suture line cephalad to the true tri-
cuspid annulus and conduction tissue.1136 The Journal of Thoracic and Cardiovascular Surgery c MInvestigation of preoperative and postoperative RV function is
another area of great interest. Most investigation is being done
with magnetic resonance imaging evaluation. Ebstein anomaly is
an RV myopathy, and all of the maneuvers that we do in the oper-
ating room do not take away the fact that a myopathy is still present.
We believe that plication or resection of the atrialized right ventricle
is reasonable and should be done at the discretion of the surgeon. We
believe that reducing the size of a markedly dilated right ventricle
might increase the efficiency of the right ventricle and perhaps indi-
rectly improve function. We know that the size of the right ventricle,
in general, gets smaller after you eliminate the regurgitant lesion. It
is not well documented at this time whether this results in improve-
ment in RV function. Magnetic resonance imaging examination
preoperatively and postoperatively should help delineate this in
the future.ay 2008
